

David A Boyd

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1733795/david-a-boyd-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

693
citations

10
h-index

23
g-index

23
ext. papers

798
ext. citations

5.2
avg, IF

3.4
L-index

#	Paper	IF	Citations
23	Absence of transmission of NDM and OXA-48 carbapenemase genes in a chronic care unit of a long-term care facility.. <i>Journal of Infection Prevention</i> , 2022 , 23, 15-19	1.1	
22	Household Transmission of Carbapenemase-producing Enterobacterales in Ontario, Canada. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4607-e4615	11.6	4
21	Emergence of Harboring Metalloenzyme in Canada. <i>MSphere</i> , 2021 , 6,	5	0
20	Analysis of an IncR Plasmid Carrying Linked to an Azithromycin Resistance Region in <i>Enterobacter hormaechei</i> Involved in an Outbreak in Quebec.. <i>Microbiology Spectrum</i> , 2021 , 9, e0199821	8.9	0
19	<i>Enterobacter</i> sp. N18-03635 harbouring blaFRI-6 class A carbapenemase, Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 486-488	5.1	3
18	Detection of Antimicrobial Resistance Using Proteomics and the Comprehensive Antibiotic Resistance Database: A Case Study. <i>Proteomics - Clinical Applications</i> , 2020 , 14, e1800182	3.1	9
17	Arrival of the rare carbapenemase OXA-204 in Canada causing a multispecies outbreak over 3 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2787-2796	5.1	3
16	Two Hypervirulent <i>Klebsiella pneumoniae</i> Isolates Producing a Carbapenemase from a Canadian Patient. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	19
15	Identification of a novel metallo- β -lactamase, CAM-1, in clinical <i>Pseudomonas aeruginosa</i> isolates from Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1563-1567	5.1	7
14	1228. Risk Factors for Contamination with Carbapenemase-Producing Enterobacterales (CPE) in Exposed Hospital Drains in Ontario, Canada. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S441-S441	1	5
13	Results from the Canadian Nosocomial Infection Surveillance Program for detection of carbapenemase-producing <i>Acinetobacter</i> spp. in Canadian hospitals, 2010-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 315-320	5.1	8
12	Characterization of OXA-48-like carbapenemase producers in Canada, 2011-14. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 626-633	5.1	17
11	Evaluation of a Modified Carbapenem Inactivation Method for Detection of Carbapenemases in <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	9
10	<i>Enterobacter cloacae</i> Complex Isolates Harboring or -Type Class A Carbapenemase Genes on Novel Chromosomal Integrative Elements and Plasmids. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	22
9	Results from the Canadian Nosocomial Infection Surveillance Program on Carbapenemase-Producing Enterobacteriaceae, 2010 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6787-6794	5.9	43
8	Vancomycin-resistant <i>Enterococcus faecium</i> harbouring vanN in Canada: a case and complete sequence of pEfm12493 harbouring the vanN operon. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2163-5	5.1	5
7	MALDI-TOF MS detection of carbapenemase activity in clinical isolates of Enterobacteriaceae spp., <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> compared against the Carba-NP assay. <i>Journal of Microbiological Methods</i> , 2015 , 111, 21-3	2.8	37

6	Molecular characterization of <i>Enterococcus faecalis</i> N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 2667-72	5.9	103
5	<i>Salmonella</i> genomic island 1 (SGI1), variant SGI1-I, and new variant SGI1-O in <i>proteus mirabilis</i> clinical and food isolates from China. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 340-4	5.9	46
4	<i>Enterococcus gallinarum</i> N04-0414 harbors a VanD-type vancomycin resistance operon and does not contain a D-alanine:D-alanine 2 (ddl2) gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1067-70	5.9	10
3	VanG-type vancomycin-resistant <i>Enterococcus faecalis</i> strains isolated in Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2217-21	5.9	31
2	<i>Enterococcus faecium</i> N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 680-3	5.1	33
1	Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3758-64	5.9	279